HU230223B1 - Substituted pyridines and pyridazines with angiogenesis inhibiting activity and pharmaceutical compositions containing them - Google Patents

Substituted pyridines and pyridazines with angiogenesis inhibiting activity and pharmaceutical compositions containing them Download PDF

Info

Publication number
HU230223B1
HU230223B1 HU0202704A HUP0202704A HU230223B1 HU 230223 B1 HU230223 B1 HU 230223B1 HU 0202704 A HU0202704 A HU 0202704A HU P0202704 A HUP0202704 A HU P0202704A HU 230223 B1 HU230223 B1 HU 230223B1
Authority
HU
Hungary
Prior art keywords
group
alkyl
short
substituted
optionally
Prior art date
Application number
HU0202704A
Other languages
English (en)
Hungarian (hu)
Inventor
Jacques P Dumas
Teddy Kite Joe
Harold C. E. Kluender
Wendy Lee
Dhanapalan Nagarathnam
Robert N. Sibley
Ning Su
Stephen James Boyer
Julie A. Dixon
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of HUP0202704A2 publication Critical patent/HUP0202704A2/hu
Publication of HUP0202704A3 publication Critical patent/HUP0202704A3/hu
Publication of HU230223B1 publication Critical patent/HU230223B1/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
HU0202704A 1999-09-28 2000-09-26 Substituted pyridines and pyridazines with angiogenesis inhibiting activity and pharmaceutical compositions containing them HU230223B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40760099A 1999-09-28 1999-09-28
US09/407,600 1999-09-28
PCT/US2000/026500 WO2001023375A2 (en) 1999-09-28 2000-09-26 Substituted pyridines and pyridazines with angiogenesis inhibiting activity

Publications (3)

Publication Number Publication Date
HUP0202704A2 HUP0202704A2 (hu) 2002-12-28
HUP0202704A3 HUP0202704A3 (en) 2003-12-29
HU230223B1 true HU230223B1 (en) 2015-10-28

Family

ID=23612752

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202704A HU230223B1 (en) 1999-09-28 2000-09-26 Substituted pyridines and pyridazines with angiogenesis inhibiting activity and pharmaceutical compositions containing them

Country Status (35)

Country Link
EP (1) EP1228063B1 (enExample)
JP (1) JP4919567B2 (enExample)
KR (3) KR100890473B1 (enExample)
CN (3) CN100422172C (enExample)
AR (3) AR025752A1 (enExample)
AT (1) ATE422494T1 (enExample)
AU (1) AU782820B2 (enExample)
BG (1) BG65860B1 (enExample)
BR (1) BRPI0014382B8 (enExample)
CA (1) CA2385817C (enExample)
CO (1) CO5200835A1 (enExample)
CZ (1) CZ304767B6 (enExample)
DE (1) DE60041548D1 (enExample)
DO (1) DOP2000000070A (enExample)
EE (1) EE05258B1 (enExample)
ES (1) ES2320525T3 (enExample)
GT (1) GT200000158A (enExample)
HR (1) HRP20020308A2 (enExample)
HU (1) HU230223B1 (enExample)
IL (3) IL148880A0 (enExample)
MA (1) MA25563A1 (enExample)
MX (1) MXPA02003156A (enExample)
MY (3) MY143377A (enExample)
NO (1) NO20021520L (enExample)
NZ (1) NZ518589A (enExample)
PA (1) PA8503201A1 (enExample)
PE (1) PE20010607A1 (enExample)
PL (1) PL205957B1 (enExample)
RS (1) RS50369B (enExample)
RU (1) RU2260008C2 (enExample)
SK (1) SK287417B6 (enExample)
TW (1) TW593315B (enExample)
UA (1) UA75053C2 (enExample)
WO (1) WO2001023375A2 (enExample)
ZA (1) ZA200202760B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2416525A1 (en) * 2000-08-09 2002-02-14 Astrazeneca Ab Indole, azaindole and indazole derivatives having vegf inhibiting activity
EP1415987B1 (en) 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Nitrogenous aromatic ring compounds as anti cancer agents
US20050019424A1 (en) * 2001-12-21 2005-01-27 Adams Paul E. Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
TWI299664B (en) 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds
EP1603566B1 (en) * 2003-03-11 2009-01-21 Novartis AG Use of isoquinoline derivatives for treating cancer and map kinase related diseases
EP1616576A4 (en) * 2003-04-08 2010-02-10 Mitsubishi Tanabe Pharma Corp SPECIFIC NAD (P) H OXIDASE HEMMER
WO2005044788A1 (ja) 2003-11-11 2005-05-19 Eisai Co., Ltd. ウレア誘導体およびその製造方法
KR100553398B1 (ko) * 2004-03-12 2006-02-16 한미약품 주식회사 티에노[3,2-c]피리딘 유도체의 제조 방법 및 이에사용되는 중간체
EP1797877A4 (en) 2004-09-13 2010-12-15 Eisai Co Ltd JOINT USE OF A SULFONAMIDE-BASED COMPOUND AND AN ANGIOGENESIS INHIBITOR
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
ATE428421T1 (de) 2004-09-17 2009-05-15 Eisai R&D Man Co Ltd Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
WO2007118602A1 (en) * 2006-04-15 2007-10-25 Bayer Healthcare Ag Compounds for treating pulmonary hypertension
WO2007136103A1 (ja) 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. 甲状腺癌に対する抗腫瘍剤
KR101472600B1 (ko) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
EP2119707B1 (en) 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
CN101481380B (zh) 2008-01-08 2012-10-17 浙江医药股份有限公司新昌制药厂 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途
BR112012003592B8 (pt) 2009-08-19 2021-05-25 Eisai R&D Man Co Ltd composição farmacêutica contendo derivado de quinolina
CA2802644C (en) 2010-06-25 2017-02-21 Eisai R & D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
EP2700403B1 (en) 2011-04-18 2015-11-25 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
WO2012166899A2 (en) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
CN105264380B (zh) 2013-05-14 2017-09-05 卫材R&D管理有限公司 用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
CN103396361B (zh) * 2013-07-24 2016-05-04 中国人民解放军第二军医大学 3,4-二氢异喹啉类抗肿瘤化合物及其制备方法与应用
CA2957005C (en) 2014-08-28 2021-10-12 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
SG11201706630UA (en) 2015-02-25 2017-09-28 Eisai R&D Man Co Ltd Method for suppressing bitterness of quinoline derivative
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
CN104804008B (zh) * 2015-03-27 2016-03-23 亿腾药业(泰州)有限公司 一种工业化生产甲磺酸特拉替尼的方法
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
CN107129502B (zh) * 2017-04-13 2022-08-05 泰州亿腾景昂药业股份有限公司 EOC315 Mod.I晶型化合物及其制备方法
BR112019023064A2 (pt) 2017-05-16 2020-06-09 Eisai R&D Man Co Ltd tratamento de carcinoma hepatocelular
JP7624404B2 (ja) * 2019-04-22 2025-01-30 ミラティ セラピューティクス,インク. Prc2阻害剤としてのナフチリジン誘導体
CN112830932B (zh) * 2020-12-25 2022-04-08 泰州亿腾景昂药业股份有限公司 特拉替尼的游离碱晶型及其制备方法与用途
KR20240115979A (ko) 2021-11-08 2024-07-26 프로젠토스 테라퓨틱스, 인크. 혈소판-유래 성장 인자 수용체(pdgfr) 알파 억제제 및 이의 용도

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1453897A (fr) * 1965-06-16 1966-07-22 Dérivés du thiophène et de thiéno pyridazines
GB1094044A (en) * 1965-07-12 1967-12-06 Vantorex Ltd Phthalazine derivatives
FR1516777A (fr) * 1966-08-02 1968-02-05 Innothera Lab Sa Dérivés du thiazole ainsi que de la thiazolo [4,5-d] pyridazine et leur préparation
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
JPH03106875A (ja) * 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd 1―(3―ピリジルメチル)フタラジン誘導体
CA2173493C (en) * 1994-08-09 2008-03-25 Nobuhisa Watanabe Fused pyridazine compounds
IL118631A (en) * 1995-06-27 2002-05-23 Tanabe Seiyaku Co History of pyridazinone and processes for their preparation
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
EP1107964B8 (en) * 1998-08-11 2010-04-07 Novartis AG Isoquinoline derivatives with angiogenesis inhibiting activity
JP4673977B2 (ja) * 1999-03-30 2011-04-20 ノバルティス アーゲー 炎症性疾患治療用フタラジン誘導体
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
PT1254138E (pt) * 2000-02-09 2005-09-30 Novartis Ag Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf

Also Published As

Publication number Publication date
BR0014382B1 (pt) 2014-04-01
CN1769282A (zh) 2006-05-10
EP1228063A2 (en) 2002-08-07
SK5912002A3 (en) 2003-01-09
BG65860B1 (bg) 2010-03-31
IL193367A (en) 2011-03-31
MY143377A (en) 2011-05-13
CN100422172C (zh) 2008-10-01
KR20020038775A (ko) 2002-05-23
WO2001023375A2 (en) 2001-04-05
HRP20020308B1 (enExample) 2013-01-31
CO5200835A1 (es) 2002-09-27
KR100895572B1 (ko) 2009-04-29
JP2003526632A (ja) 2003-09-09
RU2260008C2 (ru) 2005-09-10
MY143580A (en) 2011-05-31
AR025752A1 (es) 2002-12-11
TW593315B (en) 2004-06-21
HUP0202704A2 (hu) 2002-12-28
EE200200161A (et) 2003-08-15
DOP2000000070A (es) 2002-02-28
IL193368A (en) 2011-05-31
PA8503201A1 (es) 2002-08-26
ZA200202760B (en) 2003-10-29
ES2320525T3 (es) 2009-05-25
HK1091818A1 (zh) 2007-01-26
CN100422173C (zh) 2008-10-01
AR082231A2 (es) 2012-11-21
NZ518589A (en) 2005-03-24
PL205957B1 (pl) 2010-06-30
AR082232A2 (es) 2012-11-21
PE20010607A1 (es) 2001-07-12
AU1569601A (en) 2001-04-30
NO20021520L (no) 2002-05-23
UA75053C2 (en) 2006-03-15
SK287417B6 (sk) 2010-09-07
BR0014382A (pt) 2003-06-24
CN1420879A (zh) 2003-05-28
BRPI0014382B8 (pt) 2021-05-25
PL366342A1 (en) 2005-01-24
AU782820B2 (en) 2005-09-01
EP1228063B1 (en) 2009-02-11
CN100374435C (zh) 2008-03-12
IL193367A0 (en) 2009-02-11
YU22902A (sh) 2004-12-31
CZ20021444A3 (cs) 2002-08-14
MXPA02003156A (es) 2002-09-30
RS50369B (sr) 2009-11-10
HRP20020308A2 (en) 2004-06-30
GT200000158A (es) 2002-03-16
WO2001023375A3 (en) 2002-05-02
HUP0202704A3 (en) 2003-12-29
EE05258B1 (et) 2010-02-15
CZ304767B6 (cs) 2014-10-08
CA2385817A1 (en) 2001-04-05
MY135058A (en) 2008-01-31
KR20080086547A (ko) 2008-09-25
KR20080091505A (ko) 2008-10-13
DE60041548D1 (de) 2009-03-26
ATE422494T1 (de) 2009-02-15
JP4919567B2 (ja) 2012-04-18
CN1769283A (zh) 2006-05-10
IL148880A0 (en) 2002-09-12
CA2385817C (en) 2010-05-04
KR100890473B1 (ko) 2009-03-26
IL193368A0 (en) 2009-02-11
NO20021520D0 (no) 2002-03-26
MA25563A1 (fr) 2002-10-01
HK1091819A1 (zh) 2007-01-26
KR100895571B1 (ko) 2009-04-29
BG106637A (bg) 2003-02-28

Similar Documents

Publication Publication Date Title
TWI352086B (en) Trisubstituted amine compound
JP2022066289A (ja) カンナビノイド受容体モジュレーター
HU229514B1 (en) 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
HU229553B1 (en) 1,2-dihydropyridine compound, process for preparation of the same and use thereof
KR20030022371A (ko) 벤질리덴아미노구아니딘 및 히드록시구아니딘의멜라노코르틴 수용체 리간드로서의 용도
JP2008505907A (ja) 癌治療を目的として肝細胞増殖因子およびc−met活性を調整するキナゾリンモジュレーター
TW200823215A (en) Pyrazolopyrimidines, a process for their preparation and the use as a medicine
CN110291065A (zh) 一种新的异二氢吲哚衍生物、其药物组合物及应用
TW200806675A (en) Heterobicyclic thiophene compounds and methods of use
TW201028393A (en) Kinase inhibitors and methods of their use
TW201113272A (en) Novel pyrimidine-and triazine hepcidine antagonists
WO2007037534A1 (ja) 2-へテロアリール置換インドール誘導体
CN102617548A (zh) 作为gpr受体激动剂的双环杂芳基化合物及其组合物和应用
HUE029036T2 (en) FGF receptor (FGFR) agonist dimer compounds, methods for their preparation and their therapeutic use
DE69909209T2 (de) Pyrimidinon-derivate, diese verbindungen enthaltenden pharmazeutische zubereitungen und verfharen zu ihrer herstellung
TW201031664A (en) Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
JP2019535820A (ja) 選択性ブルトン型チロシンキナーゼ阻害剤及びその使用
CN109790144A (zh) 新型杂环化合物作为酪氨酸激酶bcr-abl抑制剂
JP7025555B2 (ja) 一過性受容体電位a1イオンチャネルの阻害
CN118076354A (zh) 用mnk抑制剂治疗偏头痛的方法
TW200927746A (en) Arylvinylazacycloalkane compounds and methods of preparation and use thereof
DE102010014426A1 (de) Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
CN108947879A (zh) Prmt i型抑制剂及其制备方法和用途
CN109863139A (zh) 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂
TWI710554B (zh) 新穎苯并咪唑化合物及其醫藥用途

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: BAYER HEALTHCARE LLC, US

Free format text: FORMER OWNER(S): BAYER CORP., US; BAYER PHARMACEUTICALS CORPORATION, US

MM4A Lapse of definitive patent protection due to non-payment of fees